Exam preparation, Self-tuition – preparation for exam
9
0
Heilbronnsalen, C458, Vån 4, Laboratory experiment, Group 5, Maxime Gestin, Lab 4: Receptor binding part 1
10
9
Heilbronnsalen, C458, Vån 4, Lecture, Anders Undén, Lecture 5. Ion channels I
12
9
Heilbronnsalen, C458, Vån 4, Lecture, Anders Undén, Lecture 10. Ligand-regulated ion channels II
12
9
Heilbronnsalen, C458, Vån 4, Lecture, Henrietta Nielsen, Lecture 13. GPCRs and G-proteins
12
9
Heilbronnsalen, C458, Vån 4, Lecture, Anders Undén, Lecture 17. Monoamines I
12
9
Heilbronnsalen, C458, Vån 4, Test, Dugga 2
12
9
Heilbronnsalen, C458, Vån 4, Lecture, Anders Undén, Lecture 21. Neurochemical aspects of pain
12
9
Heilbronnsalen, C458, Vån 4, Exam preparation, Anders Undén, Review of previous exams, Q&A
12
9
Heilbronnsalen, C458, Vån 4, Examination, Anna-Lena Ström, Omtentamen
14
9
Heilbronnsalen, C458, Vån 4, Roll call, Anna-Lena Ström, Roll Call
10
10
Heilbronnsalen, C458, Vån 4, Lecture, Anders Undén, Anna-Lena Ström, Course presentation
11
10
KÖL-K434, Vån 4, Laboratory experiment, Group 5, Maxime Gestin, Lab 4: Receptor binding part 1
17
10
Exam preparation, Self-tuition – preparation for exam
0
13
Heilbronnsalen, C458, Vån 4, Introduction, Anna-Lena Ström, Introduction for master students
15
13
Heilbronnsalen, C458, Vån 4, Presentation, Presentation and summary of lab 1-5
16
13
C472, Vån 4, Laboratory experiment, Group 1-2, Anders Undén, Lab 5: Neurosim
17
13
Heilbronnsalen, C458, Vån 4, Laboratory experiment, Group 5, Anna-Lena Ström, Lab 2: Brain anatomy
17
13
KÖL-K434, Vån 4, Laboratory experiment, Group 2, Daniel Patrick Twohig, Lab 1: Ca2+ flux part 1
17
13
KÖL-K434, Vån 4, Laboratory experiment, Group 6, Daniel Patrick Twohig, Lab 1: Ca2+ flux part 1
17
13
KÖL-K434, Vån 4, Laboratory experiment, Group 1, Daniel Patrick Twohig, Lab 1: Ca2+ flux part 1
17
13
KÖL-K434, Vån 4, Laboratory experiment, Group 4, Daniel Patrick Twohig, Lab 1: Ca2+ flux part 1
17
13
Heilbronnsalen, C458, Vån 4, Laboratory experiment, Group 1-2, Daniel Patrick Twohig, Lab 3: IP3 inhibition
17
13